Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36


What is the Optimal Rate of Invasive Coronary Angiography After Acute Coronary Syndrome? (ANZACS-QI 22).

Chan D, Ghazali S, Selak V, Lee M, Scott T, Kerr A.

Heart Lung Circ. 2019 Feb 2. pii: S1443-9506(19)30041-1. doi: 10.1016/j.hlc.2019.01.006. [Epub ahead of print]


Relationship between estimated glomerular filtration rate and incident cardiovascular disease in an ethnically diverse primary care cohort.

Church E, Poppe K, Harwood M, Mehta S, Grey C, Selak V, Marshall MR, Wells S.

N Z Med J. 2019 Mar 8;132(1491):11-26.


Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study.

Selak V, Jackson R, Poppe K, Wu B, Harwood M, Grey C, Pylypchuk R, Mehta S, Kerr A, Wells S.

Ann Intern Med. 2019 Feb 26. doi: 10.7326/M18-2808. [Epub ahead of print]


Indigenous health worker support for patients with poorly controlled type 2 diabetes: study protocol for a cluster randomised controlled trial of the Mana Tū programme.

Selak V, Stewart T, Jiang Y, Reid J, Tane T, Carswell P, Harwood M.

BMJ Open. 2018 Dec 14;8(12):e019572. doi: 10.1136/bmjopen-2017-019572.


Mana Tū: a whānau ora approach to type 2 diabetes.

Harwood M, Tane T, Broome L, Carswell P, Selak V, Reid J, Light P, Stewart T.

N Z Med J. 2018 Nov 9;131(1485):76-83.


Feasibility and reliability of clinical coding surveillance for the routine monitoring of adverse drug events in New Zealand hospitals.

Ng J, Andrew P, Muir P, Greene M, Mohan S, Knight J, Hider P, Davis P, Seddon M, Scahill S, Harrison J, Zhou L, Selak V, Lawes C, Galgali G, Broad J, Crawley M, Pevreal W, Houston N, Brott T, Ryan D, Peach J, Brant A, Bramley D.

N Z Med J. 2018 Oct 26;131(1484):46-60.


Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.

Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, Amarasekara S, Amarasena N, Billot L, de Silva AP, Fernando M, Guggilla R, Jan S, Jayawardena J, Maulik PK, Mendis S, Mendis S, Munasinghe J, Naik N, Prabhakaran D, Ranasinghe G, Thom S, Tisserra N, Senaratne V, Wijekoon S, Wijeyasingam S, Rodgers A, Patel A; TRIUMPH Study Group.

JAMA. 2018 Aug 14;320(6):566-579. doi: 10.1001/jama.2018.10359. Erratum in: JAMA. 2018 Nov 13;320(18):1940.


Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.

Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, Arroll B, Bots ML, Brown A, Crengle S, Dorairaj P, Elley CR, Grobbee DE, Harwood M, Hillis GS, Laba TL, Neal B, Peiris D, Rafter N, Reid C, Stanton A, Tonkin A, Usherwood T, Wadham A, Rodgers A.

Heart. 2019 Jan;105(1):42-48. doi: 10.1136/heartjnl-2018-313108. Epub 2018 Jun 28.


Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.

Selak V, Kerr A, Poppe K, Wu B, Harwood M, Grey C, Jackson R, Wells S.

JAMA. 2018 Jun 26;319(24):2507-2520. doi: 10.1001/jama.2018.8194.


Is general practice identification of prior cardiovascular disease at the time of CVD risk assessment accurate and does it matter?

Wells S, Poppe K, Selak V, Kerr A, Pylypchuk R, Wu B, Chan WC, Grey C, Mehta S, Gentles DG, Jackson R.

N Z Med J. 2018 May 18;131(1475):10-20.


Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe?

Selak V, Webster R.

Ther Adv Drug Saf. 2018 Feb;9(2):157-162. doi: 10.1177/2042098617747836. Epub 2017 Dec 20. Review.


Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset.

Webster R, Bullen C, Patel A, Selak V, Stepien S, Thom S, Rodgers A.

Int J Cardiol. 2017 Dec 15;249:443-447. doi: 10.1016/j.ijcard.2017.09.162. Epub 2017 Sep 20.


Are ethnic inequalities in 30-day ischaemic stroke survival emerging as treatment becomes more effective?

Sandiford P, Selak V, Ghafel M.

N Z Med J. 2016 Jul 1;129(1437):8-14.


Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter.

Selak V, Gu Y, Rafter N, Crengle S, Kerr AJ, Bullen C.

N Z Med J. 2016 May 27;129(1435):21-8.


Decision-making in an era of cancer prevention via aspirin: New Zealand needs updated guidelines and risk calculators.

Wilson N, Selak V, Blakely T, Leung W, Clarke P, Jackson R, Knight J, Nghiem N.

N Z Med J. 2016 Mar 11;129(1431):85-92.


Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease.

Selak V, Bullen C, Stepien S, Arroll B, Bots M, Bramley D, Cass A, Grobbee D, Hillis GS, Molanus B, Neal B, Patel A, Rafter N, Rodgers A, Thom S, Tonkin A, Usherwood T, Wadham A, Webster R.

Eur J Prev Cardiol. 2016 Sep;23(13):1393-400. doi: 10.1177/2047487316638216. Epub 2016 Mar 4. Review.


Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial.

Selak V, Harwood M, Raina Elley C, Bullen C, Wadham A, Parag V, Rafter N, Arroll B, Bramley D, Crengle S.

Eur J Prev Cardiol. 2016 Sep;23(14):1537-45. doi: 10.1177/2047487316637196. Epub 2016 Feb 29.


Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.

Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, Bullen C, Cass A, Crengle S, Raina Elley C, Grobbee DE, Neal B, Peiris D, Poulter N, Prabhakaran D, Rafter N, Stanton A, Stepien S, Thom S, Usherwood T, Wadham A, Rodgers A; SPACE Collaboration.

Int J Cardiol. 2016 Feb 15;205:147-156. doi: 10.1016/j.ijcard.2015.12.015. Epub 2015 Dec 14.


Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.

BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318.


TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol.

Salam A, Webster R, Singh K, Kallakuri S, Rodgers A, Prabhakaran D, Maulik PK, Jan S, Thom S, Naik N, Guggilla R, Selak V, Patel A.

Am Heart J. 2014 Feb;167(2):127-32. doi: 10.1016/j.ahj.2013.10.020. Epub 2013 Nov 6.


Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration.

Webster R, Patel A, Billot L, Cass A, Burch C, Neal B, Usherwood T, Thom S, Poulter N, Stanton A, Bots ML, Grobbee DE, Prabhakaran D, Reddy KS, Field J, Bullen C, Elley CR, Selak V, Rafter N, Wadham A, Berwanger O, Rodgers A; SPACE Collaboration.

Int J Cardiol. 2013 Dec 5;170(1):30-5. doi: 10.1016/j.ijcard.2013.10.007. Epub 2013 Oct 12.


Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial.

Selak V, Crengle S, Elley CR, Wadham A, Harwood M, Rafter N, Bullen C, Pillai A, Arroll B, Rodgers A.

Int J Equity Health. 2013 Jun 22;12:44. doi: 10.1186/1475-9276-12-44.


The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.

Elley CR, Gupta AK, Webster R, Selak V, Jun M, Patel A, Rodgers A, Thom S.

PLoS One. 2012;7(12):e52145. doi: 10.1371/journal.pone.0052145. Epub 2012 Dec 19.


IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.

Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, Bryant L, Rafter N, Hoorn SV, Wadham A, Wells S, Milne R, Jackson R, Bramley D, Rodgers A.

Contemp Clin Trials. 2011 Nov;32(6):909-15. doi: 10.1016/j.cct.2011.07.006. Epub 2011 Jul 18.


Aspirin for primary prevention: yes or no?

Selak V, Elley CR, Wells S, Rodgers A, Sharpe N.

J Prim Health Care. 2010 Jun;2(2):92-9.


Therapeutics. Intensive blood pressure control did not prevent major CV events more than standard control in type 2 diabetes.

Elley C, Selak V.

Ann Intern Med. 2010 Jul 20;153(2):JC1-4, JC1-5. doi: 10.7326/0003-4819-153-2-201007200-02004. No abstract available.


Cardiovascular treatment gaps: closing, but slowly.

Selak V, Rafter N, Parag V, Tomlin A, Vander Hoorn S, Dovey S, Rodgers A.

N Z Med J. 2009 Apr 24;122(1293):3564.


Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice.

Wells S, Furness S, Rafter N, Horn E, Whittaker R, Stewart A, Moodabe K, Roseman P, Selak V, Bramley D, Jackson R.

Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):173-8. doi: 10.1097/HJR.0b013e3282f13af4.


Gaps in primary care documentation of cardiovascular risk factors.

Rafter N, Wells S, Stewart A, Selak V, Whittaker R, Bramley D, Roseman P, Furness S, Jackson RT.

N Z Med J. 2008 Feb 15;121(1269):24-33.


Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand.

Elley CR, Kenealy T, Robinson E, Bramley D, Selak V, Drury PL, Kerse N, Pearson J, Lay-Yee R, Arroll B.

Diabetes Res Clin Pract. 2008 Mar;79(3):468-73. Epub 2007 Nov 19.


Danazol for pelvic pain associated with endometriosis.

Selak V, Farquhar C, Prentice A, Singla A.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000068. Review.


Smoking status recording in GP electronic records: the unrealised potential.

Selak V, Wells S, Whittaker R, Stewart A.

Inform Prim Care. 2006;14(4):235-41; discussion 242-5.


Will a web-based cardiovascular disease (CVD) risk assessment programme increase the assessment of CVD risk factors for Maori?

Whittaker R, Bramley D, Wells S, Stewart A, Selak V, Furness S, Rafter N, Roseman P, Jackson R.

N Z Med J. 2006 Jul 21;119(1238):U2077.


Danazol for pelvic pain associated with endometriosis.

Selak V, Farquhar C, Prentice A, Singla A.

Cochrane Database Syst Rev. 2001;(4):CD000068. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD000068.


Danazol for pelvic pain associated with endometriosis.

Selak V, Farquhar C, Prentice A, Singla A.

Cochrane Database Syst Rev. 2000;(2):CD000068. Review. Update in: Cochrane Database Syst Rev. 2001;(4):CD000068.


Supplemental Content

Support Center